Visugromab in Cachexia International Trial

Condition(s) studied

Investigational drug(s) / intervention(s)

Visugromab (CTL-002): High dose

Placebo: IV infusion

Visugromab (CTL-002): Medium dose

Visugromab (CTL-002): Low dose

Study summary

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:

* Does visugromab help participants put weight back on and have a better appetite?
* Does visugromab help participants move more and better?
* What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug).

Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

Eligibility

Primary outcome measure(s)

• Change from baseline in body weight at 12 weeks — 12 weeks
• Change from baseline in appetite at 12 weeks — 12 weeks
  Measured on the 5-item anorexia subscale of the Functional Assessment of Anorexia/Cachexia Therapy instrument (minimum score 0, maximum 20; higher is better outcome)

Trial sites (74)

+ 34 more sites — see the full list on the official registry below.

More CatalYm GmbH trials in Italy